In Taiwan, given the discrepancy between current treatment guidelines and reimbursement options, patients might require a tool to support their decision-making process when selecting a regimen for metastatic colorectal cancer, especially therapeutic strategies, and subsequent costs, along with efficacy and safety outcomes. Therefore, we developed a patient decision aid (PDA) to support patients in choosing between treatment options recommended based on the current evidence and those reimbursed by the Taiwanese National Health Insurance.
Methods
By carefully reviewing the updated data and then interpreting the clinical tool, we conducted a needs assessment using a serial questionnaire to test for a step-by-step adjustment of the PDA.
Results
Patients, their relatives, and medical team members were most concerned about outcomes, such as overall survival, progression-free survival, objective response rate, tumor shrinkage to resectable status, total medical cost, severe gastrointestinal perforation, and severe skin reaction. After a serial alpha test for quality, we performed quantitative evaluation and beta tests, revealing average scores of more than 4 points (on a scale of 1–5) for both perceptibility and utility.
Conclusions
The present findings suggest that PDAs are useful and supplement the shared decision-making practice, helping patients make decisions about preferences and consider the pros and cons of treatment regimens, along with insurance reimbursement options.
Vectibix. IV Injection, Panitumumab IV Injection (package insert).
Thousand Oaks:
Amgen, Inc., 2006.
3.
Erbitux Intravenous Injection,Cetuximab Intravenous Injection (package insert).
Indianapolis:
Eli Lilly and Company, 2018.
4.
AVASTIN, Bevacizumab Intravenous Solution (package insert). South San Francisco: Genentech, Inc., 2005.
5.
BonettiAGiulianiJMuggiaF.Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. Anticancer Res2014;
34: 423–434.
6.
WeissJMPfauPRO'ConnorES, et al.
Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results—medicare data. J Clin Oncol2011;
29: 4401–4409.
7.
YoshinoTArnoldDTaniguchiH, et al.
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol2018;
29: 44–70.
Review Manager (RevMan) [computer program]. version 5.3.
Copenhagen:
Nordic Cochrane Centre.
15.
CilibertoDStaropoliNCagliotiF, et al.
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: a classic and Bayesian meta-analysis. Crit Rev Oncol Hematol2018;
125: 69–77.
16.
AljehaniMAMorganJWGuthrieLA, et al.
Association of primary tumor site with mortality in patients receiving bevacizumab and cetuximab for metastatic colorectal cancer. JAMA Surg2018;
153: 60–67.
17.
SchwartzbergLSRiveraFKarthausM, et al.
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol2014;
32: 2240–2247.
18.
DouillardJYSienaSCassidyJ, et al.
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol2010;
28: 4697–4705.
19.
PrimroseJFalkSFinch-JonesM, et al.
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol2014;
15: 601–611.
20.
van CutsemEKöhneCHLángI, et al.
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastaticcolorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol2011;
29: 2011–2019.
21.
MaughanTSAdamsRASmithCG, et al.
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet2011;
377: 2103–2114.
22.
PeetersMForgetFKarthausM, et al.
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. ESMO Open2018;
3: e000297.
23.
TejparSStintzingSCiardielloF, et al.
Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol2017;
3: 194–201.
24.
ModestDPStintzingSvon WeikersthalLF, et al.
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget2017;
8: 105749–105760.
25.
BokemeyerCBondarenkoIHartmannJT, et al.
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol2011;
22: 1535–1546.
26.
ShitaraKYonesakaKDendaT, et al.
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. Cancer Sci2016;
107: 1843–1850.
27.
ModestDPMartensUMRiera-KnorrenschildJ, et al.
FOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO-KRK0109). J Clin Oncol2019;
37: 3401–3411.
28.
TveitKMGurenTGlimeliusB, et al.
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol2012;
30: 1755–1762.
29.
PassardiANanniOTassinariD, et al.
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol2015;
26: 1201–1207.
30.
QinSXuJWangL, et al.
First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial [abstract]. Ann Oncol2016;
27: ii141.
31.
YeLCLiuTSRenL, et al.
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol2013;
31: 1931–1938.
32.
FitzmauriceCAllenCBarberRM, Global Burden of Disease Cancer Collaborationet al.
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol2017;
3: 524–548.
33.
Van CutsemELenzHJKöhneCH, et al.
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol2015;
33: 692–700.
34.
VenookAPNiedzwieckiDLenzHJ, et al.
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA2017;
317: 2392–2401.
35.
AllegraCJRumbleRBHamiltonSR, et al.
Extended ras gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American society of clinical oncology provisional clinical opinion update 2015. J Clin Oncol2016;
34: 179–185.
36.
HeinemannVvon WeikersthalLFDeckerT, et al.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol2014;
15: 1065–1075.
37.
JacobsenMJO’ConnorAMStaceyD.Decisional needs assessment in populations: a workbook for assessing patients’ and practitioners’ decision-making needs.
Ontario, Canada:
Ottawa Hospital Research Institute, 1999, https://decisionaid.ohri.ca/docs/implement/Population_Needs.pdf (2013, accessed 19 May 2020).
38.
HoffmannTCMontoriVMdel MarC.The connection between evidence-based medicine and shared decision making. JAMA2014;
312: 1295–1296.
39.
CharlesCGafniAWhelanT.Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med1997;
44: 681–692.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
